These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25409876)

  • 1. Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.
    Alao JP; Michlikova S; Dinér P; Grøtli M; Sunnerhagen P
    BMC Cancer; 2014 Nov; 14():853. PubMed ID: 25409876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
    Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
    Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
    Kim DW; Jo YS; Jung HS; Chung HK; Song JH; Park KC; Park SH; Hwang JH; Rha SY; Kweon GR; Lee SJ; Jo KW; Shong M
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4070-6. PubMed ID: 16849418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
    Spanheimer PM; Park JM; Askeland RW; Kulak MV; Woodfield GW; De Andrade JP; Cyr AR; Sugg SL; Thomas A; Weigel RJ
    Clin Cancer Res; 2014 Apr; 20(8):2115-25. PubMed ID: 24526731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
    Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
    Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII.
    Campbell M; Trimble ER
    Circ Res; 2005 Feb; 96(2):197-206. PubMed ID: 15591231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.
    Caccia D; Miccichè F; Cassinelli G; Mondellini P; Casalini P; Bongarzone I
    Mol Cancer; 2010 Oct; 9():278. PubMed ID: 20955590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
    Nelson-Taylor SK; Le AT; Yoo M; Schubert L; Mishall KM; Doak A; Varella-Garcia M; Tan AC; Doebele RC
    Mol Cancer Ther; 2017 Aug; 16(8):1623-1633. PubMed ID: 28500237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
    Spanheimer PM; Cyr AR; Gillum MP; Woodfield GW; Askeland RW; Weigel RJ
    Ann Surg; 2014 Apr; 259(4):793-9. PubMed ID: 24045439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
    Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
    J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of RET tyrosine kinase by SU5416.
    Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
    J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
    Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
    Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
    Schweppe RE; Kerege AA; Sharma V; Poczobutt JM; Gutierrez-Hartmann A; Grzywa RL; Haugen BR
    Thyroid; 2009 Aug; 19(8):825-35. PubMed ID: 19500021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
    Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
    J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.